Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 303Carcinoma, Non-Small-Cell Lung 240Prostatic Neoplasms 196Neoplasms 190Lung Neoplasms 149Multiple Myeloma 141Neoplasm Metastasis 110Colorectal Neoplasms 104Melanoma 97Ovarian Neoplasms 90Leukemia, Myeloid, Acute 82Pancreatic Neoplasms 76Lymphoma 76Leukemia, Lymphocytic, Chronic, B-Cell 71Brain Neoplasms 69Carcinoma, Renal Cell 67Squamous Cell Carcinoma of Head and Neck 62Lymphoma, Non-Hodgkin 62Carcinoma, Hepatocellular 61Hematologic Neoplasms 60Urinary Bladder Neoplasms 58Head and Neck Neoplasms 56Triple Negative Breast Neoplasms 55Recurrence 54Glioblastoma 53Uterine Cervical Neoplasms 51Lymphoma, Follicular 51Endometrial Neoplasms 50Stomach Neoplasms 46Sarcoma 46

Interventions

cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Non-small Cell Lung Cancer × 90 days × Clear all
NCT05099172 2026-05-13

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Bayer

Phase 1/2 Active not recruiting
370 enrolled 1 FDA
Thoracic

Advanced Non-small Cell Lung Cancer

NCT06269133 2026-05-08

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Regeneron Pharmaceuticals

Active not recruiting
1,000 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡